|Bid||140.14 x 200|
|Ask||140.27 x 200|
|Day's Range||139.38 - 143.35|
|52 Week Range||139.38 - 209.22|
|PE Ratio (TTM)||144.30|
|Dividend & Yield||0.92 (0.63%)|
|1y Target Est||N/A|
It's never good news for a stock when a chief financial officer suddenly departs--and that's certainly the case for Shire (SHPG) today, which announced that CFO Jeff Poulton would be leaving the company to join a startup. A CFO's departure is often taken as a sign that deeper issues could emerge at a company, and that's probably what's happening at Shire. The stock, after all, has dropped 14% so far this year, as investors fretted about the impact of weakening generic sales following Teva Pharmaceutical Industries' (TEVA) earnings on specialty pharmaceutical stocks of all stripes.
Shire plc (SHPG) submitted a Marketing Authorization Application (MAA) for lifitegrast for the treatment of dry eye disease in Europe.
One of the state’s biggest biotech employers, Shire plc, has applied for European approval for its potential blockbuster eye drop to treat dry eye disease, sold by the name of Xiidra in the U.S. The drug, a twice-a-day eye drop that goes by the generic name of lifitegrast, was approved in the U.S. in August 2016. It’s touted as the “first and only” drug in the world to treat the signs and symptoms of dry eye disease, and competes head-to-head with Restasis, a similarly-priced drug sold by Allergan plc (AGN) that’s approved to increase tear production due to inflammation.